Biologics

KICVentures Appoints Jake Lubinski as CEO of NanoFUSE Biologics

BOSTON (PRWEB) MARCH 19, 2020

NanoFUSE Biologics, LLC, the only biologics company with a bioactive glass FDA-cleared to be combined with DBM, announced it has chosen Jake Lubinski, the current President of NanoFUSE Biologics, LLC and President of Commercialization and Acquisition of parent company KICVentures, LLC, as its new CEO effective March 16th 2019.

In January 2019, NanoFUSE Biologics current CEO, Dr. Kingsley Chin, MD announced he would step down as CEO to focus on further expanding KICVentures and its healthcare portfolio.

“Jake is uniquely qualified to take on this role as CEO given his track record of success over the years, which will serve NanoFUSE Biologics and KICVentures investors well,” said Dr Kingsley Chin, MD.

Lubinski joined KICVentures in 2010 and has served in multiple executive roles within KICVentures portfolio companies since 2013. Over the course of his career with KICVentures he has led operational, business development, and company growth and acquisition initiatives that have helped advance KICVentures as a leader in healthcare private equity.

“I am excited to bring expertise and values that are aligned with our organization and I am confident in my ability to work alongside our talented leadership team and deliver on our ambitious goals to give patients around the world access to NanoFUSE,” said Lubinsk. “NanoFUSE Biologics is positioned to be the worldwide leader in bioactive glass and synthetic biologics.”

About NanoFUSE Biologics

NanoFUSE Biologics is a biologically enhanced synthetic therapeutic that combines osteoinductive DBM with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in general orthopedic applications. NanoFUSE Biologics is a KICVentures portfolio company.

About KICVentures

KICVentures is a private investment holding company founded by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed, NanoFUSE and SpineFrontier. It has headquarters in Boston, MA.

Print Friendly, PDF & Email
Tags

Chris J. Stewart

Chris currently serves as Chief Executive Officer of Surgio Health as well as COO at Ortho Spine Partners. Chris has close to 20 years of healthcare management experience with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that solve real problems that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help drive better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button
Close